Unihealth Hosp

Why is Unihealth Hospitals Ltd falling/rising?

As of 11-Jun, Unihealth Hospitals Ltd's stock price is at 465.75, down slightly by 0.17%. Despite this minor decline, the stock has shown strong performance with a year-to-date increase of 55.72% and a remarkable growth of 153.81% over the past year.

As of 11-Jun, Unihealth Hospitals Ltd's stock price is currently at 465.75, reflecting a slight decrease of 0.8 points, or 0.17%. Despite this minor decline, the stock has shown strong performance over various periods. Over the past week, it has risen by 6.21%, and in the last month, it has increased by 6.46%. Year-to-date, the stock has surged by 55.72%, and over the past year, it has experienced a remarkable growth of 153.81%. <BR><BR>The stock is currently trading above its moving averages for 5 days, 20 days, 50 days, 100 days, and 200 days, indicating a generally positive trend. However, there is a noted decrease in investor participation, with delivery volume falling by 18.83% compared to the 5-day average, which could be contributing to the current price decline. Despite this drop, the stock remains liquid enough for trading, suggesting that while there may be short-term fluctuations, the overall performance remains strong relative to the benchmark Sensex, which has declined by 11.36% year-to-date.

Which are the latest news on Unihealth Hosp?

What does Unihealth Hosp do?

Unihealth Hospitals Ltd is a micro-cap company in the hospital industry, incorporated in 2010 and recently renamed in 2023. It currently reports no sales or profit, with a market cap of INR 725 Cr and key metrics including a P/E of 29.00 and a debt-equity ratio of 0.20.

Overview: <BR>Unihealth Hospitals Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 2010 under the name "Unihealth Consultancy Private Limited." It changed its status to a public limited company and its name to "Unihealth Consultancy Limited" on April 26, 2023. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 725 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.20 <BR>Return on Equity: 18.77% <BR>Price-to-Book: 5.32 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the peers of the Unihealth Hosp?

Unihealth Hosp's peers include Dr Agarwal's Eye, Shalby, GPT Healthcare, and others. Unihealth Hosp leads in 1-year returns at 154.25%, while several peers show below-average growth and negative returns.

Peers: The peers of Unihealth Hosp are Dr Agarwal's Eye, Shalby, GPT Healthcare, Chandan Healthca, Aprameya Enginee, Lotus Eye Hospit, Asarfi Hospital, and KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Dr Agarwal's Eye, Shalby, Chandan Healthca, Asarfi Hospital, and KMC Speciality, and the rest. Growth is Excellent at Unihealth Hosp, Dr Agarwal's Eye, Chandan Healthca, while Below Average growth is seen at Shalby, GPT Healthcare, and Aprameya Enginee, and the rest. Capital Structure is Excellent at GPT Healthcare and Unihealth Hosp, Good at Shalby, Chandan Healthca, and Aprameya Enginee, while Below Average is noted at Lotus Eye Hospit, and the rest.<BR><BR>Return Snapshot: Unihealth Hosp has the highest 1-year return at 154.25%, while Aprameya Enginee has the lowest at -8.67%, indicating that Unihealth Hosp significantly outperforms its peers. Additionally, Chandan Healthca, Aprameya Enginee, and Shalby have negative six-month returns.

Is Unihealth Hosp overvalued or undervalued?

As of December 3, 2025, Unihealth Hospital is considered undervalued with an attractive valuation grade, highlighted by a PE Ratio of 33.89, strong growth metrics, and significant recent performance, outperforming peers like Max Healthcare and Apollo Hospitals.

As of 3 December 2025, the valuation grade for Unihealth Hosp has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 33.89, an EV to EBITDA of 13.29, and a PEG Ratio of 0.94, which suggests that the stock is priced favorably relative to its growth prospects.<BR><BR>In comparison to its peers, Unihealth Hosp stands out with a significantly lower PE Ratio than Max Healthcare, which is at 74.7, and Apollo Hospitals, which has a PE of 61.84. This positions Unihealth as an attractive option in the hospital sector, especially considering its strong ROCE of 22.89% and ROE of 11.27%. Notably, while the stock has experienced a decline of 16.95% over the past week, it has shown impressive growth of 90.36% over the last month, outperforming the Sensex, which only increased by 0.86% in the same period.

Is Unihealth Hosp technically bullish or bearish?

As of December 1, 2025, Unihealth Hosp's trend is mildly bullish, supported by a bullish MACD and moving averages, though bearish RSI readings suggest some momentum weakness.

As of 1 December 2025, the technical trend for Unihealth Hosp has changed from bullish to mildly bullish. The current stance is mildly bullish, with key indicators supporting this view. The weekly MACD remains bullish, while the daily moving averages also indicate a bullish trend. However, the weekly and monthly RSI readings are bearish, suggesting some weakness in momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, providing additional support. Overall, the mixed signals from the RSI and MACD indicate a cautious bullish sentiment.

How has been the historical performance of Unihealth Hosp?

Unihealth Hosp has demonstrated consistent growth in net sales and profitability over the past five years, with net sales increasing from 26.21 Cr in Mar'21 to 55.59 Cr in Mar'25, and profit after tax rising from 4.95 Cr to 15.15 Cr. However, cash flow from operating activities turned negative in Mar'25, indicating recent challenges.

Answer:<BR>The historical performance of Unihealth Hosp shows a consistent growth trend in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Unihealth Hosp's net sales have increased from 26.21 Cr in Mar'21 to 55.59 Cr in Mar'25, demonstrating a strong upward trajectory. Total operating income followed a similar pattern, rising to 55.59 Cr in Mar'25 from 26.21 Cr in Mar'21. The company’s total expenditure, excluding depreciation, also grew, reaching 37.10 Cr in Mar'25, up from 19.69 Cr in Mar'21. Operating profit (PBDIT) has shown significant improvement, climbing from 8.95 Cr in Mar'21 to 21.31 Cr in Mar'25. Profit before tax increased from 5.47 Cr in Mar'21 to 17.28 Cr in Mar'25, while profit after tax rose from 4.95 Cr to 15.15 Cr in the same period. The consolidated net profit also reflected this growth, moving from 5.01 Cr in Mar'21 to 15.14 Cr in Mar'25. The company's total assets increased from 58.34 Cr in Mar'21 to 132.09 Cr in Mar'25, with total liabilities rising from 58.39 Cr to 132.09 Cr. However, cash flow from operating activities turned negative in Mar'25 at -3.00 Cr, contrasting with positive cash flows in previous years. Overall, Unihealth Hosp has shown robust growth in sales and profitability, despite recent challenges in cash flow.

How big is Unihealth Hosp?

As of 24th July, Unihealth Hospitals Ltd has a market capitalization of 271.00 Cr, classified as a Micro Cap, with Shareholder's Funds of 85.45 Cr and Total Assets of 110.21 Cr; however, no valid financial data is available for the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Unihealth Hospitals Ltd has a market capitalization of 271.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: No valid financial data is available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 85.45 Cr and Total Assets totaling 110.21 Cr.

Who are the top shareholders of the Unihealth Hosp?

The top shareholder of Unihealth Hosp is Anurag Ratan Kumar Sha, holding 32.47% of the shares, with Anant Wealth Consultants as the largest public shareholder at 3.94%. Individual investors collectively own 20.78%, and there are no pledged promoter holdings or shares held by mutual funds or foreign institutional investors.

The top shareholders of Unihealth Hosp include the promoters, with Anurag Ratan Kumar Sha holding the largest share at 32.47%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Anant Wealth Consultants, which holds 3.94%. Additionally, individual investors collectively own 20.78% of the shares.

When is the next results date for Unihealth Hosp?

No Upcoming Board Meetings

Has Unihealth Hosp declared dividend?

No Dividend History Available